Enveric Biosciences Inc. has announced that it will issue unregistered series G and series H warrants to purchase up to 328,802 shares of common stock each, as part of a registered direct offering and concurrent private placement. The series G and H warrants will have an exercise price of $4.16 per share, will be immediately exercisable, with the series G warrants expiring five years and the series H warrants expiring eighteen months after the effective date of a registration statement registering the shares issuable upon exercise of the warrants. The offering is expected to close on or about January 28, 2026, subject to customary closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-004055), on January 28, 2026, and is solely responsible for the information contained therein.